Valuation: Jazz Pharmaceuticals plc

Market Cap 15.5B 14.05B 13B 11.73B 22.1B 1,462B 22.88B 156B 61.9B 781B 58.19B 56.95B 2,479B P/E 2026 *
62.6x
P/E 2027 * 14.6x
Enterprise Value 18.35B 16.63B 15.38B 13.88B 26.15B 1,730B 27.07B 185B 73.26B 924B 68.86B 67.4B 2,934B EV / Sales 2026 *
3.82x
EV / Sales 2027 * 3.27x
Free-Float
96.76%
Yield 2026 *
-
Yield 2027 * -
1 day+0.49%
1 week+2.89%
Current month+11.84%
1 month+12.65%
3 months-1.39%
6 months+5.59%
Current year+42.09%
1 week 235.89
Extreme 235.89
249.99
1 month 202.3
Extreme 202.3
249.99
Current year 156.95
Extreme 156.95
266.38
1 year 156.95
Extreme 156.95
266.38
3 years 95.49
Extreme 95.49
266.38
5 years 95.49
Extreme 95.49
266.38
10 years 86.88
Extreme 86.88
266.38
Manager TitleAgeSince
Chief Executive Officer 54 11/08/2025
Director of Finance/CFO 62 01/03/2024
Chief Tech/Sci/R&D Officer 54 01/08/2023
Director TitleAgeSince
Chairman 62 01/03/2003
Director/Board Member 65 18/01/2012
Director/Board Member 66 01/01/2010
Date Insider Type Main position Quantity % Market Cap. Importance
11/3/26 A Sell

Chief Executive Officer

-1,000 0.0015%
11/2/26 A Sell

Founder

-6,000 0.0092%
10/6/26 A Sell

Chief Executive Officer

-2,000 0.0031%
Change 5-day change 1-year change 3-year change Capi.($)
+0.49%+2.89%+71.23%+92.62% 15.5B
+1.26%+6.61%+40.79%+145.27% 1,286B
+0.79%+3.45%+45.84%+92.04% 688B
+0.20%+1.28%+26.97%+114.41% 521B
-0.44%+3.69%+41.45%+68.91% 386B
+0.55%+0.70%+59.02%+45.79% 364B
-0.12%+0.74%+28.39%+58.54% 302B
+0.37%+0.37%+3.33%+37.27% 287B
-0.30%+1.14%+38.29%+70.56% 252B
+0.08%+0.71%+34.44%+123.99% 208B
Average +0.29%+2.16%+38.97%+84.94% 431B
Weighted average by Cap. +0.54%+3.25%+37.82%+98.95%

Financials

2026 *2027 *
Net sales 4.81B 4.36B 4.03B 3.64B 6.85B 453B 7.09B 48.4B 19.19B 242B 18.04B 17.66B 769B 5.07B 4.59B 4.25B 3.83B 7.22B 478B 7.47B 51.01B 20.23B 255B 19.01B 18.61B 810B
Net income 278M 252M 233M 211M 397M 26.25B 411M 2.8B 1.11B 14.02B 1.04B 1.02B 44.52B 1.13B 1.03B 950M 857M 1.62B 107B 1.67B 11.41B 4.53B 57.09B 4.25B 4.16B 181B
Net Debt 2.85B 2.58B 2.39B 2.15B 4.06B 268B 4.2B 28.65B 11.36B 143B 10.68B 10.45B 455B 1.05B 955M 883M 797M 1.5B 99.36B 1.55B 10.61B 4.21B 53.07B 3.95B 3.87B 168B
Projected Income Statement - Annual - Jazz Pharmaceuticals plc
Logo Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, ABS-1230, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
Employees
2,890
Date Price Change Volume
13/11/26 $241.55 +0.49% 496,703
12/11/26 $240.37 -3.17% 584,415
11/11/26 $248.24 +1.14% 592,854
10/11/26 $245.43 +0.77% 576,714
09/11/26 $243.55 +3.74% 886,048
Trader
Investor
Global
Quality
ESG MSCI
A
MarketScreener Ratings - Jazz Pharmaceuticals plc
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
241.55USD
Average target price
297.59USD
Spread / Average Target
+23.20%
  1. Stock Market
  2. Stocks
  3. JAZZ Stock